Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics is supported by a compelling mix of commercial momentum, clinical validation, and pipeline optionality, with 3Q26 revenue of $122MM beating estimates and cash of $382.3MM providing balance-sheet support. Its lead therapy showed durable efficacy across melanoma and NSCLC, including a 62.5% ORR and 29.2% CR rate in frontline melanoma, while the company expands into sarcoma and prepares a planned sBLA in 2027 for NSCLC. Growth in the ATC network to over 100 sites, improving manufacturing turnaround, and sustained demand for Amtagvi and Proleukin strengthen confidence that the platform can scale beyond a single indication.

Iovance Biotherapeutics is facing a weaker fundamental outlook because lifileucel’s NSCLC efficacy appears stable at a 24.6% ORR in 69 patients, yet durability remains uncertain as estimated median DOR slipped to about 10 months in 2026 from roughly 12 months in 2025 and more responses ended within six months. Safety also remains a concern, with all 10 infused patients experiencing grade 4 cytopenias and eight having grade ≥3 treatment-related adverse events, while the company withheld updated median DOR, PFS, and OS data that would better support the case. The stock is further pressured by major regulatory, commercial, and competitive risk, since FDA and foreign approvals are uncertain, R&D spending is substantial, and rivals in melanoma and emerging CAR-T approaches could limit the addressable market.